JP2017537070A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537070A5 JP2017537070A5 JP2017522084A JP2017522084A JP2017537070A5 JP 2017537070 A5 JP2017537070 A5 JP 2017537070A5 JP 2017522084 A JP2017522084 A JP 2017522084A JP 2017522084 A JP2017522084 A JP 2017522084A JP 2017537070 A5 JP2017537070 A5 JP 2017537070A5
- Authority
- JP
- Japan
- Prior art keywords
- immune checkpoint
- stranded antisense
- cancer
- antisense oligonucleotide
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462068141P | 2014-10-24 | 2014-10-24 | |
| US62/068141 | 2014-10-24 | ||
| PCT/EP2015/074271 WO2016062722A1 (en) | 2014-10-24 | 2015-10-20 | Combination |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537070A JP2017537070A (ja) | 2017-12-14 |
| JP2017537070A5 true JP2017537070A5 (enExample) | 2018-11-29 |
| JP6687612B2 JP6687612B2 (ja) | 2020-04-22 |
Family
ID=54347516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522084A Active JP6687612B2 (ja) | 2014-10-24 | 2015-10-20 | 組合せ |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20190194654A1 (enExample) |
| EP (2) | EP3209778B1 (enExample) |
| JP (1) | JP6687612B2 (enExample) |
| KR (3) | KR20230128139A (enExample) |
| CN (2) | CN107106590B (enExample) |
| AU (1) | AU2015335029B2 (enExample) |
| CA (1) | CA2965034C (enExample) |
| DK (1) | DK3209778T3 (enExample) |
| ES (1) | ES2727154T3 (enExample) |
| HU (1) | HUE043227T2 (enExample) |
| IL (2) | IL251813A0 (enExample) |
| PL (1) | PL3209778T3 (enExample) |
| RU (1) | RU2744841C2 (enExample) |
| SG (2) | SG10202105879XA (enExample) |
| TR (1) | TR201906415T4 (enExample) |
| WO (1) | WO2016062722A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10519504B2 (en) | 2009-05-11 | 2019-12-31 | Berg Llc | Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| KR101933732B1 (ko) | 2011-04-04 | 2018-12-28 | 버그 엘엘씨 | 중추 신경 시스템 종양들의 치료 방법 |
| CA2909094C (en) | 2013-04-08 | 2023-06-27 | Berg Llc | Methods for the treatment of cancer using coenzyme q10 combination therapies |
| IL276423B2 (en) | 2013-09-04 | 2024-05-01 | Berg Llc | Pharmaceutical preparations containing coenzyme Q10 for use in cancer treatment |
| EP3148573A4 (en) * | 2014-05-29 | 2017-11-15 | Medimmune, LLC | Ox40l fusion proteins and uses thereof |
| SG10202105879XA (en) * | 2014-10-24 | 2021-07-29 | Astrazeneca Ab | Combination |
| AU2015349680A1 (en) | 2014-11-21 | 2017-06-08 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| SG11201707383PA (en) | 2015-03-13 | 2017-10-30 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| SG11201708804WA (en) | 2015-05-07 | 2017-11-29 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| EP3371311B1 (en) | 2015-11-06 | 2021-07-21 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| WO2017087576A1 (en) | 2015-11-16 | 2017-05-26 | Berg Llc | Methods of treatment of temozolomide-resistant glioma using coenzyme q10 |
| AU2016364889B2 (en) | 2015-12-02 | 2024-01-04 | Agenus Inc. | Antibodies and methods of use thereof |
| EP4059957A1 (en) | 2016-02-05 | 2022-09-21 | Orionis Biosciences BV | Bispecific signaling agents and uses thereof |
| SG11201807474SA (en) * | 2016-04-25 | 2018-11-29 | Medimmune Llc | Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies |
| CN109563141A (zh) | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
| EP3454887B1 (en) | 2016-05-13 | 2021-01-20 | Orionis Biosciences BV | Targeted mutant interferon-beta and uses thereof |
| WO2018018018A1 (en) * | 2016-07-21 | 2018-01-25 | Berg Llc | Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| JP7204643B2 (ja) | 2016-10-24 | 2023-01-16 | オリオニス バイオサイエンシズ ビーブイ | 標的変異インターフェロン－ガンマおよびその使用 |
| EP3538152A4 (en) | 2016-11-09 | 2020-09-30 | Agenus Inc. | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE |
| US20190256603A1 (en) * | 2016-11-11 | 2019-08-22 | Medimmune, Llc | Anti-pd-l1 and anti-ctla-4 antibodies for treating non-small cell lung cancer |
| EP3576765B1 (en) | 2017-02-06 | 2025-07-16 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| US11384154B2 (en) | 2017-02-06 | 2022-07-12 | Orionis Biosciences BV | Targeted chimeric proteins and uses thereof |
| US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
| JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| WO2019023525A1 (en) * | 2017-07-28 | 2019-01-31 | Dana-Farber Cancer Institute, Inc. | ENHANCED IMMUNOTHERAPY OF CANCER USING TARGETED TRANSCRIPTION MODULATORS |
| WO2019148089A1 (en) | 2018-01-26 | 2019-08-01 | Orionis Biosciences Inc. | Xcr1 binding agents and uses thereof |
| CA3088009A1 (en) * | 2018-02-12 | 2019-08-15 | Codiak Biosciences, Inc. | Methods and compositions for macrophage polarization |
| JPWO2019177159A1 (ja) * | 2018-03-15 | 2021-02-25 | 国立大学法人北海道大学 | 癌免疫療法併用剤 |
| CN112513297B (zh) | 2018-03-28 | 2024-10-22 | 得克萨斯州大学系统董事会 | 鉴定从外排体分离的dna中的表观遗传改变 |
| JP7663357B2 (ja) * | 2018-04-25 | 2025-04-16 | メディミューン リミテッド | ヒト抗ｐｄ－ｌ１抗体の配合物 |
| WO2020097350A1 (en) | 2018-11-08 | 2020-05-14 | Orionis Biosciences, Inc. | Modulation of dendritic cell lineages |
| CN109675040B (zh) * | 2018-12-31 | 2021-07-30 | 清华大学 | 治疗乳腺癌的组合物及其应用 |
| CN113365659B (zh) * | 2019-01-31 | 2023-08-18 | 正大天晴药业集团股份有限公司 | 抗pd-l1抗体治疗头颈癌的用途 |
| WO2020206105A1 (en) * | 2019-04-02 | 2020-10-08 | Board Of Regents, The University Of Texas System | Combinations of transcription inhibitors and immune checkpoint inhibitors for treatment of disease |
| KR20220004664A (ko) * | 2019-04-26 | 2022-01-11 | 가부시키가이샤 야쿠르트 혼샤 | 퀴놀린카르복사미드 유도체를 사용하는 면역 체크 포인트 저해제 병용 요법 |
| US20220304972A1 (en) * | 2019-08-23 | 2022-09-29 | Sumitomo Dainippon Pharma Co., Ltd. | Combination therapy and biomarker indicating efficacy thereof |
| EP4037693A1 (en) * | 2019-09-30 | 2022-08-10 | Astrazeneca AB | Combination treatment for cancer |
| WO2021072286A1 (en) * | 2019-10-09 | 2021-04-15 | City Of Hope | Cancer combination treatments using anti-stat3 nucleic acid conjugates |
| CN114599372A (zh) | 2019-11-04 | 2022-06-07 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的组合疗法 |
| JP7674354B2 (ja) * | 2019-12-05 | 2025-05-09 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 肝線維症および線維症に関連する他の疾患に対するエキソソームベースの療法 |
| WO2021228836A1 (en) * | 2020-05-13 | 2021-11-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Recombinant proteins with ox40 activating properties |
| WO2022076596A1 (en) * | 2020-10-06 | 2022-04-14 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
| EP4493695A2 (en) * | 2022-03-15 | 2025-01-22 | Dicerna Pharmaceuticals, Inc. | Combination of stat3 targeting oligonucleotides and pd-l1 inhibitors |
| EP4649173A1 (en) | 2023-01-13 | 2025-11-19 | Akrivia Biomedics Limited | Method of profiling diseases |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US5821332A (en) | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
| US6242566B1 (en) | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
| US6159694A (en) | 1999-04-08 | 2000-12-12 | Isis Pharmaceuticals Inc. | Antisense modulation of stat3 expression |
| NZ530583A (en) | 1999-08-23 | 2005-10-28 | Dana Farber Cancer Inst Inc | Novel B7-4 molecules and uses therefor |
| US7158164B2 (en) | 2003-08-29 | 2007-01-02 | Fuji Photo Film Co., Ltd. | Thermal development method and apparatus |
| WO2005027962A1 (en) | 2003-09-18 | 2005-03-31 | Isis Pharmaceuticals, Inc. | 4’-thionucleosides and oligomeric compounds |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| SI2650020T1 (sl) | 2005-05-06 | 2017-03-31 | Providence Health & Services - Oregon Technology Transfer | Trimerični OX40 imunoglobulinski fuzijski protein in postopek za njegovo uporabo |
| HRP20151102T1 (xx) | 2005-07-01 | 2015-11-20 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1) |
| US20070243184A1 (en) | 2005-11-08 | 2007-10-18 | Steven Fischkoff | Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy |
| DK2066684T3 (da) | 2006-05-11 | 2012-10-22 | Isis Pharmaceuticals Inc | 5´-Modificerede bicycliske nukleinsyreanaloge |
| EP2125852B1 (en) | 2007-02-15 | 2016-04-06 | Ionis Pharmaceuticals, Inc. | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom |
| WO2008109494A1 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting stat3 gene expression and uses thereof |
| CA2699995A1 (en) | 2007-09-17 | 2009-03-26 | Intradigm Corporation | Compositions comprising stat3 sirna and methods of use thereof |
| US20100285039A1 (en) | 2008-01-03 | 2010-11-11 | The Johns Hopkins University | B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells |
| AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
| KR20250091300A (ko) | 2008-12-09 | 2025-06-20 | 제넨테크, 인크. | 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도 |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| DK2504364T3 (da) | 2009-11-24 | 2017-11-06 | Medimmune Ltd | Målrettede bindemidler mod b7-h1 |
| WO2012135736A2 (en) | 2011-04-01 | 2012-10-04 | Isis Pharmaceuticals, Inc. | Modulation of signal transducer and activator of transcription 3 (stat3) expression |
| MX338353B (es) | 2011-04-20 | 2016-04-13 | Medimmune Llc | Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1. |
| CA2863818A1 (en) | 2012-02-06 | 2013-08-15 | Brendan CURTI | Cancer treatment and monitoring methods using ox40 agonists |
| CA2865899A1 (en) | 2012-03-02 | 2013-09-06 | William Redmond | Dual ox40 agonist/il-2 cancer therapy methods |
| WO2013134467A1 (en) * | 2012-03-07 | 2013-09-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Selective histone deactylase 6 inhibitors |
| RS58576B1 (sr) | 2012-10-31 | 2019-05-31 | Ionis Pharmaceuticals Inc | Tretman raka |
| SG10202105879XA (en) * | 2014-10-24 | 2021-07-29 | Astrazeneca Ab | Combination |
-
2015
- 2015-10-20 SG SG10202105879XA patent/SG10202105879XA/en unknown
- 2015-10-20 CA CA2965034A patent/CA2965034C/en active Active
- 2015-10-20 CN CN201580057882.8A patent/CN107106590B/zh active Active
- 2015-10-20 TR TR2019/06415T patent/TR201906415T4/tr unknown
- 2015-10-20 DK DK15784628.8T patent/DK3209778T3/da active
- 2015-10-20 AU AU2015335029A patent/AU2015335029B2/en active Active
- 2015-10-20 ES ES15784628T patent/ES2727154T3/es active Active
- 2015-10-20 EP EP15784628.8A patent/EP3209778B1/en active Active
- 2015-10-20 KR KR1020237028459A patent/KR20230128139A/ko not_active Ceased
- 2015-10-20 RU RU2017117664A patent/RU2744841C2/ru active
- 2015-10-20 HU HUE15784628A patent/HUE043227T2/hu unknown
- 2015-10-20 WO PCT/EP2015/074271 patent/WO2016062722A1/en not_active Ceased
- 2015-10-20 JP JP2017522084A patent/JP6687612B2/ja active Active
- 2015-10-20 CN CN202211353077.8A patent/CN115920007A/zh active Pending
- 2015-10-20 SG SG11201703219WA patent/SG11201703219WA/en unknown
- 2015-10-20 KR KR1020177013607A patent/KR20170072928A/ko not_active Ceased
- 2015-10-20 US US15/521,185 patent/US20190194654A1/en not_active Abandoned
- 2015-10-20 PL PL15784628T patent/PL3209778T3/pl unknown
- 2015-10-20 EP EP19166017.4A patent/EP3550019A1/en active Pending
- 2015-10-20 KR KR1020257036604A patent/KR20250161048A/ko active Pending
-
2017
- 2017-04-20 IL IL251813A patent/IL251813A0/en unknown
-
2022
- 2022-10-13 US US18/046,173 patent/US20230374503A1/en active Pending
-
2023
- 2023-07-23 IL IL304663A patent/IL304663A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537070A5 (enExample) | ||
| RU2017117664A (ru) | Комбинация | |
| Beatty et al. | The biological underpinnings of therapeutic resistance in pancreatic cancer | |
| Nicolai et al. | A combination of cisplatin and 5-fluorouracil with a taxane in patients who underwent lymph node dissection for nodal metastases from squamous cell carcinoma of the penis: treatment outcome and survival analyses in neoadjuvant and adjuvant settings | |
| Xie et al. | MicroRNAs as regulators, biomarkers and therapeutic targets in the drug resistance of colorectal cancer | |
| Fernando et al. | BCL6 evolved to enable stress tolerance in vertebrates and is broadly required by cancer cells to adapt to stress | |
| JP2018508593A5 (enExample) | ||
| Hainsworth et al. | Paclitaxel/carboplatin with or without belinostat as empiric first‐line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial | |
| JP2018516911A5 (enExample) | ||
| Huang et al. | Wnt/β-catenin inhibitor ICG-001 enhances the antitumor efficacy of radiotherapy by increasing radiation-induced DNA damage and improving tumor immune microenvironment in hepatocellular carcinoma | |
| Wisdom et al. | Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma | |
| JP2017506227A5 (enExample) | ||
| JP2019506403A5 (enExample) | ||
| Hata et al. | Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection | |
| JP2015532292A5 (enExample) | ||
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| FI2547205T3 (fi) | Uusia menetelmiä syövän kantasolujen kohdentamiseksi | |
| Ranjan et al. | Targeting CDK9 for the treatment of glioblastoma | |
| Liu et al. | MiR-29b reverses oxaliplatin-resistance in colorectal cancer by targeting SIRT1 | |
| Ngoi et al. | A tale of two checkpoints: ATR inhibition and PD-(L) 1 blockade | |
| Wilson et al. | Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer | |
| Rudnick et al. | Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies | |
| Bai et al. | Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells | |
| JP2017537927A5 (enExample) | ||
| Wakelee et al. | Cooperative Group Research Efforts in Lung Cancer 2008: Focus on Advanced-Stage Non–Small-Cell Lung Cancer |